Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
NXT007 Prophylaxis in Pediatric Patients With Hemophilia A
NCT07838194Phase 3Not yet recruiting
- Sponsor
- Roche
- Start
- Nov 2026
- Primary completion
- Sep 2028
01
Overview
Phase 3, open-label, single-arm trial of zemocimig in hemophilia A, sponsored by Roche. Primary endpoint: Annualized Bleed Rate for Treated Bleeds. Planned start Nov 2026; status: not yet recruiting.
02
Drugs
zemocimig
03
Conditions
hemophilia A
Beyond the preview
Go deeper on NCT07838194.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT07838194.